Blogroll
HIV/AIDS networks
Links
- bilaterals.org
- Fix the Patent Laws!
- FTA Malaysia
- HAI Europe
- Health Action International (HAI)
- Intellectual Property Watch
- Lawyers Collective HIV/AIDS
- MSF Access Campaign
- Patent Opposition Database
- Public Citizen
- Stop EU-India FTA
- Stop Peru FTA
- Third World Network
- Treatment Action Group
- UAEM Europe
- UAEM evidence collection
- Universities Allied for Essential Medicines (UAEM)
Archives
-
Recent Posts
- On Announcement of All Oral MDR TB regimen by Indian Government
- Modi visit to US: Trump appearance signals importance of India
- After ‘Howdy Modi’, Trump and Modi likely to sign trade deal
- US – India Relations: President Trump To Sign New Trade Deal With Indian PM Modi?
- India-US trade talks: Trading lives?
Categories
Category Archives: Regions
Why pharmaceuticals could be the prescription for trade warfare that truly hurts America
Source: Maclean’s | June 12, 2018 What began as a trade skirmish over Donald Trump’s imposition of a 10-per-cent tariff on Canadian steel and aluminum is now clearly a trade war. The miasma is only just lifting from the G7 summit in Charlevoix, Que., in which … Continue reading
Posted in Canada, US Trade tools
Leave a comment
South African Cabinet approves new Intellectual Property Policy
Source: Fix the Patent Laws | May 24, 2018 The Fix the Patent Laws Coalition (FTPL) welcomes the news today that the Cabinet of the Government of South Africa has approved the new Intellectual Property (IP) Policy. After nine years of … Continue reading
Posted in Africa, Fix the patent law, IPR policy, Patent, Uncategorized
Leave a comment
Canada-EU Trade Deal Will Cost Canadians Hundreds Of Millions In Extra Drug Costs: PBO It will take longer for generic drugs to reach the market under the terms of CETA.
Source: Huffpost | April 27, 2018 OTTAWA — An extension of drug patent protections in the Canada-EU free trade deal could end up costing Canadians an estimated $392 million a year, and federal coffers up to $270 million more annually, … Continue reading
Posted in Canada, CETA, Drug prices
Leave a comment
Breaking news for access to biological medicines – Brazilian court nixes biological drug eculizumab patent, says more could follow
Source: BioCentury | April 21, 2018 A Brazilian court unanimously ruled Friday to remove patent protection for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), opening the door for production of biosimilar versions in the country. In a statement, Brazil’s Attorney General Office said … Continue reading
Moment of truth for global TB response
On Thursday 16 November 2017, Russian president Vladimir Putin told a hall full of health ministers in Moscow that TB is a “serious problem”, and said, “I am confident that the only way we can stand up against this truly global threat … Continue reading
Posted in BRICS, R&D, Tuberculosis (TB), Uncategorized
Leave a comment
BRICS roots for affordable medicines
Public health targets should be placed above trade deals, says J.P. Nadda By Vidya Krishnan, The Hindu | December 17, 2016 Union Health Minister J.P. Nadda has pressed for public health targets to be placed above trade deals. “Trade regimes … Continue reading
Posted in BRICS, TRIPS plus, Uncategorized
Leave a comment
Open Letter to Ambassadors (in India) of RCEP negotiating countries by Delhi Network of Positive People
Open Letter to Ambassadors of RCEP negotiating countries Member countries Must Consider the Impact of RCEP on Access to Medicines in Developing Countries Don’t trade our lives away! We are writing to you on behalf of the Delhi Network of … Continue reading